Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
Timotius Ivan Hariyanto, Devina Adella Halim, Claudia Jodhinata, Theo Audi Yanto, Andree Kurniawan
Clinical and Experimental Pharmacology and Physiology, doi:10.1111/1440-1681.13488
Currently, there is no widely acceptable and proven effective treatment for coronavirus disease 2019 (COVID-19). Colchicine has been shown to offer a benefit in reducing the inflammation in several inflammatory diseases. This study aims to analyze the efficacy of colchicine administration and outcomes of COVID-19. We systematically searched the PubMed and Europe PMC database using specific keywords related to our aims until January 29, 2021. All articles published on COVID-19 and colchicine treatment were retrieved. The quality of the study was assessed using the Newcastle-Ottawa Scale (NOS) tool for observational studies and Revised Cochrane risk-of-bias tool for randomized trials (RoB 2) for clinical trial studies. Statistical analysis was done using Review Manager 5.4 software. A total of eight studies with 5778 COVID-19 patients were included in this meta-analysis. This meta-analysis showed that the administration of colchicine was associated with improvement of outcomes of COVID-19 [OR 0.43 (95% CI 0.34-0.55), p < 0.00001, I 2 = 0%, fixed-effect modelling] and its subgroup which comprised of reduction from severe COVID-19 [OR 0.44 (95% CI 0.31-0.63), p < 0.00001, I 2 = 0%, fixed-effect modelling] and reduction of mortality rate from COVID-19 [OR 0.43 (95% CI 0.32-0.58), p < 0.00001, I 2 = 0%, fixed-effect modelling]. Our study suggests the routine use of colchicine for treatment modalities of COVID-19 patients. More randomized clinical trial studies are still needed to confirm the results from this study.
References
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J Clin Med
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Della-Torre, Campochiaro, Cavalli, Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study, Ann Rheum Dis
Della-Torre, Della-Torre, Kusanovic, Treating COVID-19 with colchicine in community healthcare setting, Clin Immunol
Hariyanto, Halim, Jodhinata, Yanto, Kurniawan, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis, Clin Exp Pharmacol Physiol
Hariyanto, Hardi, Kurniawan, Efficacy of Lopinavir/Ritonavir compared with standard care for treatment of coronavirus disease 2019 (COVID-19): a systematic review, Infect Disord Drug Targets,
doi:10.2174/1871526520666201029125725Hariyanto, Japar, Kwenandar, Inflammatory and hematologic markers as predictors of severe outcomes in COVID-19 infection: a systematic review and meta-analysis, Am J Emerg Med
Hariyanto, Kurniawan, Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection, Transfus Apher Sci
Hariyanto, Kurniawan, Statin therapy did not improve the inhospital outcome of coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr
Hariyanto, Kurniawan, Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection, Diabetes Metab Syndr
Hariyanto, Kurniawan, Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection, J Med Virol
Hariyanto, Putri, Arisa, Situmeang, Kurniawan, Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis, Arch Gerontol Geriatr
Hariyanto, Putri, Situmeang, Kurniawan, Dementia is a predictor for mortality outcome from coronavirus disease 2019 (COVID-19) infection, Eur Arch Psychiatry Clin Neurosci,
doi:10.1007/s00406-020-01205-zHariyanto, Rizki, Kurniawan, Anosmia/Hyposmia is a good predictor of coronavirus disease 2019 (COVID-19) infection: a meta-analysis, Int Arch Otorhinolaryngol
Li, Liu, Mao, Predictive values of neutrophil-tolymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis, Crit Care
Margulis, Pladevall, Riera-Guardia, Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank, Clin Epidemiol
Piantoni, Colombo, Airò, The rationale for the use of colchicine in COVID-19: comments on the letter by Cumhur Cure M et al, Clin Rheumatol
Pinzon, Arango, Betancur, Clinical outcome of patients with COVID-19 pneumonia treated with corticosteroids and colchicine in Colombia,
doi:10.21203/rs.3.rs-94922/v1Rodriguez-Nava, Garcia, Yanez-Bello, Chung, Garcia et al., Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study, Crit Care
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID-19 infection, Can J Infect Dis Med Microbiol
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, new use, Curr Pharmacol Rep
Sterne, Savović, Page, RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Vitiello, Ferrara, Pelliccia, Granata, Porta, Cytokine storm and colchicine potential role in fighting SARS-CoV-2 pneumonia, Ital J Med
